Market news

Phathom Pharmaceuticals (PHAT) has an average rating of Buy and mean price target of $23.70, accordi

FLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in September: 2026 Cantor Global Healthcare Conference in New York, NYDate: Wednesday, September 9, 2026Fireside Chat: 10:55 am EDTManagement to par

Detailed price information for Phathom Pharmaceuticals Inc (PHAT-Q) from The Globe and Mail including charting and trades.

The latest update on Phathom Pharmaceuticals centers on a reset in valuation anchors, with fair value moving from US$23.70 to US$21.50 as analysts revisit their price targets. This change reflects a more cautious tone in recent research, where Q2 results, revised 2026 revenue guidance, and fresh views on Voquezna's commercial path are all feeding into how targets are being set. As you read on, you will see what is driving the evolving narrative and how to keep track of the key signals. Stay...

~1.7 million total VOQUEZNA® prescriptions filled to dateRecord Q2 2026 net revenues of $74.3 million, increased 88% vs. Q2 2025 and 27% vs. Q1 2026Q2 operating expenses of $63.1 million, reduced by 33% vs. Q2 2025Initiating Phase 3 clinical trial evaluating as-needed dosing of VOQUEZNA® in patients with Non-Erosive GERD (NERD)Updated full-year 2026 financial guidanceConference call and webcast today, July 30, 2026, at 8:00 a.m. EDT FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Phathom P

Phathom Pharmaceuticals Inc (PHAT) achieves milestone profitability and strong revenue growth, but faces physician friction in the prior authorization process for Voquezna.

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of +100.00% and +1.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Phathom Pharmaceuticals (NASDAQ:PHAT) reported second-quarter 2026 revenue growth of 88% year over year and said it achieved positive operating profit excluding stock-based compensation for the first time in its history, reaching the milestone one quarter ahead of its prior plan. The company report

Phathom Pharmaceuticals (PHAT) reported Q2 non-GAAP net loss Thursday of $0.00 per diluted share, na

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDTFLORHAM PARK, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, July 30, 2026, to report its second quarter 2026 financial results and provide a business update. A live webcast and additi